842133-18-0
![(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇](https://stcdn.activebiopharma.com/active/ABP000358.png)
842133-18-0
编号ABP000358
化学名称(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇
英文名称 Canagliflozin/
MDL: MFCD18251436
分子式C24H25FO5S
分子量444.521
纯度 >98%
化学名称 : (1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇
CAS : 842133-18-0
英文名称: Canagliflozin/
英文同义词: CANAGLIFLOZIN
溶解度:Unknown
储存条件:at -20℃ 2 years
生物活性
Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.[1][2] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]
参考文献
- ^ New J&J diabetes drug effective in mid-stage study, Jun 26, 2010
- ^ Edward C. Chao (2011). "Canagliflozin". Drugs of the Future 36 (5): 351-357. doi:10.1358/dof.2011.36.5.1590789.
- ^ Prous Science: Molecule of the Month November 2007
-
盐酸芬戈莫德
162359-56-0
-
Odanacatib,MK-0822,MK0822/MK-0822
603139-19-1
-
![2,3-二氢-5,6-二甲氧基-2-{[(1-苯甲基)-4-哌啶基]甲基}-1H-茚-1-酮盐酸盐](https://stcdn.activebiopharma.com/active/ABP000298.png)
2,3-二氢-5,6-二甲氧基-2-{[(1-苯甲基)-4-哌啶基]甲基}-1H-茚-1-酮盐酸盐
120011-70-3
-
达帕菲尼
1195765-45-7
Copyright © 2015-2025 活性医药. All rights reserved. Support by Moldb.
浙公网安备 33010802003999号